```markdown
---
application_number: 210526Orig1s000
drug_name: Dyanavel XR
dosage_forms: 
  - 5 mg
  - 10 mg
  - 15 mg
  - 20 mg
active_ingredient: amphetamine
application_type: NDA
submission_classification: 505(b)(2)
facility_name: Tris Pharma, Inc.
facility_fei: 3004712471
initial_submission_date: 2017-09-25
amendment_date: 2020-07-22
previous_action_letter_date: 2018-07-25
proprietary_name_status: Acceptable pending approval
regulatory_contacts:
  - name: CAPT Kofi Ansah, PharmD, RAC
    title: Senior Regulatory Project Manager
    phone: (301) 796-4158
    email: Kofi.Ansah@fda.hhs.gov
fda_signatories:
  - name: Tiffany R. Farchione, MD
    title: Director, Division of Psychiatry
    office: Office of Neuroscience, Office of New Drugs
  - name: Mitchell Mathis, MD
    title: Director, Division of Psychiatry Products
    office: Office of Drug Evaluation I
status: Complete Response — Not Approvable in Current Form
---

## Critical Data

- **Application Number:** 210526Orig1s000  
- **Drug Name (Proprietary):** Dyanavel XR  
- **Active Ingredient:** Amphetamine  
- **Dosage Forms:** 5 mg, 10 mg, 15 mg, 20 mg extended-release tablets  
- **Application Type:** NDA – 505(b)(2)  
- **Initial NDA Submission Date:** September 25, 2017  
- **Date of Complete Response Amendment:** July 22, 2020  
- **Date of Prior Action Letter:** July 25, 2018  
- **Manufacturer Facility FEI:** 3004712471 (Tris Pharma, Inc.)  
- **Proprietary Name Review Status:** Acceptable pending final approval  
- **Regulatory Contact:** CAPT Kofi Ansah, PharmD, RAC — (301) 796-4158  
- **Amendment Status:** Not Approvable—Deficiencies Not Resolved  
- **Required Actions:** Resubmit within 1 year of CR Letter; marked "RESUBMISSION"  

---

# Center for Drug Evaluation and Research  
**Application Number:** 210526Orig1s000  
**Other Action Letters**  

---

## NDA 210526 - Complete Response

**To:**  
Emory Partners, LLC  
Attention: Norma J. Cappetti  
Regulatory Agent  
2031 Route 130  
Monmouth Junction, NJ 08852  

**Subject:** Dyanavel XR (amphetamine) extended-release tablets 5 mg, 10 mg, 15 mg, and 20 mg  

Please refer to your New Drug Application (NDA) dated and received September 25, 2017, and your amendments submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.

We acknowledge receipt of your amendment dated July 22, 2020, which constituted a complete response to our July 25, 2018, action letter.

We have completed our review and have determined that we cannot approve this application in its present form. Our review findings and recommendations follow.

---

### Facility Inspections

During a recent inspection of the Tris Pharma, Inc. (FEI: 3004712471) manufacturing facility for this application, our field investigator conveyed deficiencies. Satisfactory resolution of these deficiencies is required before this application may be approved.

---

### Prescribing Information

We reserve comment on the proposed labeling until the application is otherwise adequate. We encourage you to review the labeling review resources on the PLR Requirements for Prescribing Information and Pregnancy and Lactation Labeling Final Rule websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI).

Resources:  
- [PLR Requirements for Prescribing Information](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm)  
- [Pregnancy and Lactation Labeling Final Rule](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm)

---

### Medication Guide

Add the following bolded statement or appropriate alternative to the carton and container labels per 21 CFR 208.24(d):

> **"ATTENTION PHARMACIST: Each patient is required to receive the accompanying Medication Guide."**

---

### Proprietary Name

Please refer to correspondence dated October 20, 2020, which addresses the proposed proprietary name, **Dyanavel XR**. This name was found acceptable pending approval of the application in the current review cycle. Please resubmit the proposed proprietary name when you respond to the application deficiencies.

---

### Safety Update

When responding to the deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). Include data from all nonclinical and clinical studies/trials of the drug regardless of indication, dosage form, or dose level.

Include the following:

1. Detailed description of any significant changes or findings in the safety profile.
2. Incorporation of new safety data into the discontinuations, serious and common adverse events sections:
   - Present new data in same format as original submission.
   - Present tabulations combining new and original data.
   - Include comparison tables of adverse event frequencies.
   - Provide separate tables for frequencies for other indications.
3. Retabulation of reasons for premature trial discontinuation.
4. Case report forms and narrative summaries for:
   - Each patient who died during a clinical trial.
   - Patients who did not complete a trial due to adverse events.
   - Serious adverse events.
5. Changes in incidence of common, less serious adverse events.
6. Updated exposure information (e.g., number of subjects, person time).
7. Summary of worldwide experience and updated estimate of use in other countries.
8. English translations of any current approved foreign labeling not previously submitted.

---

### Other

Within one year after the date of this letter, you must resubmit or take another action under 21 CFR 314.110. If no action is taken, this may be considered a request to withdraw the application under 21 CFR 314.65. An extension request may be submitted.

A resubmission must:

- Fully address all listed deficiencies.
- Be clearly marked with **"RESUBMISSION"** in large, bolded font at the beginning of the cover letter.
- Clearly state it is a complete response to the deficiencies outlined in this letter.

Partial responses will not be processed and will not start a new review cycle.

To request a meeting with us, submit a request per the draft guidance:  
[Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products](https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM590547)

The drug product may not be legally marketed until we notify you in writing that the application is approved.

---

**Contact:**  
CAPT Kofi Ansah, PharmD, RAC  
Senior Regulatory Project Manager  
Phone: (301) 796-4158  
Email: Kofi.Ansah@fda.hhs.gov

**Sincerely,**  
Tiffany R. Farchione, MD  
Director, Division of Psychiatry  
Office of Neuroscience  
Office of New Drugs  
Center for Drug Evaluation and Research  

---

## NDA 210526 - Complete Response (Additional Letter)

**To:**  
Tris Pharma, Inc.  
Attention: Norma J. Cappetti  
Vice President, Regulatory Affairs  
2033 Route 130, Suite D  
Monmouth Junction, NJ 08852  

---

### Facility Inspections

1. During a recent inspection of the Tris Pharma, Inc. (FEI: 3004712471) manufacturing facility, deficiencies were identified. These must be satisfactorily resolved before approval.

---

### Regulatory

2. The 505(b)(2) application relies upon NDA 011522 for Adderall Tablets. A Paragraph IV certification was submitted for U.S. Patent Number 6,384,020 (‘020 patent), but documentation of required notice under 21 CFR 314.52(e) was not provided.

You are reminded to:

- Notify FDA within 14 days if legal action is filed within 45 days of receipt of notice.

---

### Prescribing Information

3. Comment on the labeling is reserved until otherwise adequate. Use the SRPI checklist to ensure format compliance. Submit updated content in SPL format per guidance:  
[Structured Product Labeling](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

---

### Carton and Container Labeling

4. Revise carton/container labeling:  
   - The **established name** should be reduced to **½ the size** of the proprietary name.  
   - You may also consider **increasing the size** of the proprietary name proportionately.

---

### Medication Guide

5. Add the following bolded statement to the carton and container labels per 21 CFR 208.24(d):

> **"ATTENTION PHARMACIST: Each patient is required to receive the enclosed Medication Guide."**

---

### Proprietary Name

6. Refer to correspondence dated April 16, 2018, regarding the proprietary name **Dyanavel XR**. It was found acceptable pending application approval within the current cycle. Please resubmit the name when addressing deficiencies.

---

### Other

If you do not resubmit the application or take other action under 21 CFR 314.110 within one year, it may be considered a request for withdrawal under 21 CFR 314.65. Extension requests may be submitted.

Resubmissions must:

- Fully address all deficiencies.
- Be clearly marked with **"RESUBMISSION"** in large, bold font at the start of the cover letter.
- State that it is a complete response to the deficiencies outlined in the letter.

Partial responses will not be reviewed or initiate a new review cycle.

To request a meeting or teleconference, follow guidance as described:  
[Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products](https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM590547)

The drug product may not be legally marketed until approval notification is issued.

**Contact:**  
CAPT Kofi Ansah, PharmD, RAC  
Senior Regulatory Project Manager  
Phone: (301) 796-4158  
Email: Kofi.Ansah@fda.hhs.gov

**Sincerely,**  
Mitchell Mathis, MD  
Director, Division of Psychiatry Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research
```